I en klinisk studie med ReFacto AF hos tidigare behandlade patienter (PTP) var incidensen för faktor VIII- inhibitorer primärt säkerhetsmått. ###>In a clinical study with ReFacto AF in previously treated patients (PTPs), the incidence of factor VIII inhibitors was the primary safety endpoint.